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Abstract 26 
 27 
OBJECTIVE: Although high-dose rifampicin holds promise for improving tuberculosis 28 
disease control by eradication of persistent bacteria, the optimal dose of rifampicin which 29 
kills persistent bacteria and shortens the treatment duration is unknown.  30 
METHODS: The Cornell mouse model was used to test the efficacy of rifampicin in elevated 31 
dose combined with isoniazid and pyrazinamide to kill actively growing and persistent bacilli 32 
and to measure relapse rate. Persistent bacteria were evaluated using Mycobacterium 33 
tuberculosis culture supernatant containing resuscitation promoting factors. Pharmacokinetic 34 
parameters and dose-dependent activity on cultivable and persistent bacilli were determined.  35 
RESULTS: Increasing doses of rifampicin in combination with isoniazid and pyrazinamide 36 
resulted in dose-dependent faster bacterial clearance.  Evaluated both on solid media and in 37 
culture filtrate containing resuscitation promoting factors, a regimen containing a standard 38 
dose of rifampicin at 10 mg/kg over 14 weeks failed to achieve organ sterility. In contrast, 39 
higher doses of rifampicin achieved organ sterility in a much shorter time of 8 to 11 week.  40 
Disease relapse, which occurred in 86% of mice treated with the standard regimen for 14 41 
weeks, was completely prevented by rifampicin doses of 30 mg/kg and above.  42 
Conclusions: In the treatment of murine tuberculosis, a rifampicin dose of 30 mg/kg was 43 
sufficient to eradicate persistent M. tuberculosis, allowing shorter treatment duration without 44 
disease relapse. 45 
 46 
 47 
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 49 
 50 
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 52 
 53 
 54 
 55 
 56 
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Introduction  58 
 59 
TB remains one of the most prevalent and lethal infectious diseases worldwide, despite of the 60 
advent of anti-TB drugs and global healthcare initiatives, leading to approximately 2 million 61 
deaths annually.
1
 Although the current drug regimen is effective, 6 months of chemotherapy 62 
are necessary to achieve a cure.  The long duration of therapy leads to poor patient 63 
compliance which gives rise to high relapse rates (7-13%) and the emergence of drug-64 
resistant strains.
2
 Thus, shortening the duration of chemotherapy is of significant clinical 65 
benefit. Unfortunately, under the current paradigm, it takes more than 6 years to bring a new 66 
drug from bench to bedside, and more than 20 years for novel drug combinations to emerge.
3
 67 
This problem is amplified by the fact that tubercle bacilli can become dormant and persistent, 68 
undetectable by conventional tests. The persistent bacteria are tolerant to current TB drugs 69 
and difficult to eradicate using the dose levels in the current drug regimen.
4, 5
 Therefore, to 70 
bridge the gap, there is an urgent need to optimize the doses of the drugs that are already used 71 
in the standard treatment regimen to maximize their bactericidal and sterilizing activities.
6
  72 
Of the current anti-tuberculous drugs, rifampicin was introduced at suboptimal doses.
6, 7
  73 
Rifampicin exhibits bactericidal activity, killing actively growing organisms and sterilizing 74 
activity, killing the persisting bacilli that are responsible for relapse.
6, 8-10
 It can be used at 75 
higher doses without serious adverse effects.
11-14
 Previous studies showed that high-dose 76 
rifampicin therapy up to 35 mg/kg is well-tolerated in man
14-16
 and increases the rate of 77 
tuberculosis clearance.
15
 Similar observations were made in mice 
13, 17-19
 with a maximum 78 
tolerable dose of 160 mg/kg per day.
19
 Recent results of a randomized clinical trial in South 79 
Africa and Tanzania by the PanACEA consortium suggested that rifampicin at 35 mg/kg was 80 
more efficacious than the standard rifampicin dose regimen by increasing culture conversion 81 
time in liquid medium.
20
 However, it is not known if rifampicin at 35 mg/kg is able to shorten 82 
the treatment duration and provides a low relapse rate. We have showed that M. tuberculosis 83 
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forms persistent bacteria which are dependent on culture filtrate (CF) containing resuscitation 84 
promoting factors 
21
  to recommence multiplication. We demonstrated for the first time that a 85 
high-dose rifampicin drug regimen was able to kill CF-dependent persistent bacteria, 86 
enabling a shortened treatment duration in mice without disease relapse.
13
  However, in our 87 
previous study, we only used one high dose of the drug (50 mg/kg). It is therefore crucial to 88 
find the minimum dose size of rifampicin capable of killing persistent bacteria with a 89 
favorable toxicity profile to patients.  90 
Herein, we studied the therapeutic effects of incremental doses of rifampicin in combination 91 
with isoniazid and pyrazinamide in the Cornell mouse model. We measured the rate of 92 
elimination of bacterial cfu counts and relapse rates. We detected and quantified persistent 93 
bacilli in cfu count-free organs using M. tuberculosis culture filtrates.    94 
Materials and methods 95 
Bacterial strains and growth conditions  96 
M. tuberculosis strain H37Rv was mouse-passaged and grown in 7H9 medium supplemented 97 
with 10% albumin dextrose complex (ADC; Becton and Dickinson, UK) and containing 98 
0.05% Tween 80 at 37°C without disturbance for 15 days. The culture was subsequently 99 
stored at -70°C for animal infection. To determine the viable counts prior to infection, colony 100 
forming unit (cfu) counting was performed prior to freezing and once again after thawing.  101 
cfu counting was carried out by plating serial 10-fold dilutions of the cultures on 7H11 agar 102 
medium supplemented with oleic albumin dextrose complex (OADC, Becton and 103 
Dickinson, UK). Colonies were counted after incubation of the plates at 37°C for 3 to 4 104 
weeks and viability was expressed as Log cfu/mL.  The cultures were subsequently diluted in 105 
PBS and used for inoculations in mice.  All culture media were made selective by the 106 
addition of polymyxin B 200 U/mL, carbenicillin 100 mg/L, trimethoprim 20 mg/L and 107 
amphotericin B 10 mg/L (Selectatab, Mast Diagnostica GmbH).  Human medicines of 108 
Page 4 of 25
Journal of Antimicrobial Chemotherapy: under review
Journal of Antimicrobial Chemotherapy
Confidential: for peer review only
5 
 
rifampicin (Rifadin capsules, Sanofi Aventis), isoniazid (isoniazid tablets, Focus) and 109 
pyrazinamide (Zinamide tablets, Genus Pharmaceuticals) were used in this study.  110 
Cornell mouse model   111 
Rifampicin at different dose sizes in combination with isoniazid and pyrazinamide was tested 112 
using the Cornell mouse model.
22, 23
   The model was conducted using the experimental 113 
design and procedure described previously.
24
 Briefly, as shown in Table 1, at 3 weeks after 114 
M. tuberculosis H37Rv infection, treatment was given to female BALB/c mice for 14 weeks 115 
with 150 mg/kg pyrazinamide, 25 mg/kg isoniazid combined with 10, 20, 30, 40 and 50 116 
mg/kg rifampicin by daily oral administration for 5 days per week. A sample of 4 mice was 117 
sacrificed at the beginning of the treatment and 8 mice was sacrificed 2
nd
, 4
th
, 6
th
, 8
th
, 11
th
 and 118 
14
th
 week of treatment to monitor cfu counts. The organ homogenates from 6
th
 to 14
th
 week 119 
were cultured in selective Kirchner liquid medium for 4 weeks with subsequent sub-culturing 120 
onto selective Löwenstein-Jensen slopes for a further 4 weeks.  121 
Immediately after termination of 14 weeks of chemotherapy, the remaining mice were 122 
administered 0.5 mg/mouse of hydrocortisone acetate by daily oral administration for 8 123 
weeks to suppress their host immunity, cfu counts from lungs and spleen were performed to 124 
determine disease relapse.   125 
The animal husbandry guidelines and all animal experiments were performed according to 126 
the Animals Scientific Procedures Act, 1986 (an Act of the Parliament of the United 127 
Kingdom 1986 c. 14) (Home Office Project licence Number 70/7077) with approval from St 128 
George’s, University of London ethics committee.  129 
Pharmacokinetics of rifampicin in BALB/c mice 130 
Pharmacokinetic (PK) profiles of rifampicin were determined in uninfected and infected mice 131 
in a dose-ranging study with regimens matching those used in the Cornell mouse model 132 
which were administered orally by gavage. There were three BALB/c mice in 2 parallel 133 
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uninfected or infected groups (total n=12 each). The infected group was treated previously 134 
with each of these drug regimens for 8 weeks. After both groups were given the drug 135 
regimens, serial venous blood samples (20 µL) were collected at time points 1, 2, 3, 4, 5, 6, 8 136 
and 24 hours post-dose by tail puncture and mixed with 40 µl of water. The blood samples 137 
were stored at -80°C and subsequently transported in dry ice to GlaxoSmithKline Tres Cantos 138 
for bioanalysis. The concentrations of rifampicin in the blood were determined by UPLC-139 
MSMS assay. PK parameters were calculated using a noncompartmental analysis model 140 
(NCA) in the R software package (v 3.3.2).    141 
Resuscitation of M. tuberculosis in mouse lungs and spleens 142 
For resuscitation of M. tuberculosis grown in mouse organs, culture filtrates containing 143 
resuscitation promoting factor (RPF) were used as described previously.
13, 21, 24
   M. 144 
tuberculosis H37Rv was grown in 7H9 medium for 15 to 20 days until an optical density of 1 145 
to 1.5 was reached.  The cultures were harvested by centrifugation at 3000 g for 15 minutes 146 
and sterilized by filtration with 0.2 µm filter (Sartorius) twice. The culture filtrates were 147 
made selective by addition of polymyxin B 200000 U/L, carbenicillin 100 mg/L, 148 
trimethoprim 20 mg/L and amphotericin B 10 mg/L (Selectatab, Mast Diagnostica GmbH).  149 
Broth counting of lungs and spleens was performed as serial 10-fold dilutions in triplicate in 150 
which 0.5 mL of tissue homogenates were added to 4.5 mL of the culture filtrates. At 10-day 151 
intervals over a 2-month period of incubation at 37°C, the broth cultures were examined for 152 
visible turbidity changes.  The patterns of positive and negative growth tubes will be used to 153 
calculate the most probable number (MPN) of the bacilli.
25
  154 
Growth of M. tuberculosis in turbid tubes was confirmed by colonial morphology on 7H11 155 
agar plates.  The absence of microorganisms other than mycobacteria from turbid tubes was 156 
confirmed by plating on blood agar medium (Oxoid) and Sabouraud dextrose agar (Oxoid).  157 
In order to assess the sterility of culture filtrates free of M. tuberculosis, tubes containing 158 
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culture filtrates were incubated at 37°C for 2 months to ensure  the absence of M. 159 
tuberculosis.  160 
Statistical analysis  161 
A simple model for monoexponential bacterial growth and elimination was used.
24, 26
  162 
Standard errors of parameter estimates were calculated using the method outlined by Landaw 163 
et al. 
27
  with the Jacobian of model parameter sensitivities estimated using a numerical 164 
central difference method. The datasets comprised from multiple individual subject animals 165 
were treated as a naïve pool for data analysis purposes  
28
 rather than using the average of the 166 
data at each time-point. The significance of differences between model parameter estimates 167 
under different therapies was examined with pairwise Z-tests incorporating a Bonferroni 168 
correction of 15 (including a comparison versus 50 mg/kg rifampicin monotherapy from 169 
previous data)  
13
,  where P values <0.0033 would be considered significant. The significance 170 
of differences between the relapse rates was determined with pairwise Fisher’s exact tests 171 
with a Bonferroni correction of 15, with P values <0.0033 considered significant.  172 
RESULTS 173 
Treatment with regimens containing different dose sizes of rifampicin in the 174 
Cornell mouse model  175 
We investigated the effect of rifampicin at 10, 20, 30, 40 and 50 mg/kg in combination 176 
regimens with fixed standard doses of isoniazid and pyrazinamide on the rate of bacterial 177 
eradication and relapse in the Cornell mouse model.  As shown in Table 2 and Fig 1a, there 178 
was a rifampicin dose-dependent increase in the rate of eradication of cfu counts in the lungs. 179 
At rifampicin 10 and 20 mg/kg regimens, the rate of pulmonary bacterial eradication was 180 
slow showing 99% kill at 3.5 weeks and at 2.5 weeks, respectively. Treatment with 181 
rifampicin 30, 40 and 50 mg/kg increased the rate of bacterial eradication (99% kill at 1.8, 1.6 182 
and 1.4 weeks, respectively). Undetectable M. tuberculosis cfu counts were achieved in 183 
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mouse lungs after 14 weeks treatment for 10 mg/kg, 11 weeks for 20 mg/kg, 8 weeks for 30 184 
and 40 mg/kg and 6 weeks with 50 mg/kg of rifampicin containing regimens (Table 2). A 185 
similar dose response trend was observed in spleens except cfu count free organs were 186 
achieved at 6 weeks for both 40 and 50 mg/kg rifampicin regimens (Table 2 and Fig 1b). 187 
These activities were confirmed by the estimates of the exponential rate constants 188 
(logarithmic base 10) for net bacterial elimination during treatment (knet_with_drug) in both lung 189 
and spleen cfu count profiles versus time (Table 3). The elimination rate constants become 190 
faster (i.e. greater in magnitude) with increasing dose, in a linear relationship in both lungs 191 
and spleens (Fig. 1c and 1d).  In the cfu count free organs, no tubercle bacilli were recovered 192 
as confirmed by negative cultures of the organ homogenates in selective Kirchner medium. 193 
No outward signs of toxicity or abnormal behavior were observed in any of the mice treated 194 
with all doses of rifampicin containing regimens. 195 
Pharmacokinetics of rifampicin in combination with isoniazid and 196 
pyrazinamide  197 
Rifampicin blood concentrations after administration of rifampicin containing regimens with 198 
isoniazid and pyrazinamide were examined over a period of 24 hour in both M. tuberculosis 199 
infected and uninfected BALB/c mice.  As shown in Fig 2, there was a linear, dose-200 
proportional increase in the exposure of rifampicin as indicated by both maximal 201 
concentration of rifampicin (Cmax) (Fig 2a) and the overall drug exposure (AUC) (Fig 2b) in 202 
both uninfected and infected mice.  The dose linearity of the rifampicin PK in this range of 203 
doses was further supported by a plot of clearance versus dose from each regimen (Fig 2c). 204 
Clearance (equal to Dose/AUC) was shown to be approximately constant at ~0.04 L/h/kg in 205 
both infected and uninfected animals at each dose level. Both AUC and Cmax of rifampicin 206 
were similar between infected and uninfected animals at all the doses examined (< 30% 207 
difference in either measure at all doses uninfected versus infected).   208 
Page 8 of 25
Journal of Antimicrobial Chemotherapy: under review
Journal of Antimicrobial Chemotherapy
Confidential: for peer review only
9 
 
Post-treatment level of persisters in the Cornell mouse model 209 
In order to investigate the effect of different rifampicin dose regimens on the post-treatment 210 
level of persisters through RPF-induced resuscitation, lung and spleen homogenates at the 211 
weeks of treatment when cfu counts reached zero for each of the regimens were incubated 212 
with CF containing RPFs. As shown in Table 4, after 14 weeks of treatment with the 213 
rifampicin 10 mg/kg regimen, despite cfu cultures being negative, the number of RPF-214 
dependent persisters was still high. At 11 weeks post-treatment, there were significant levels 215 
of CF-resuscitated bacilli in lungs and spleens for the rifampicin 20 mg/kg regimen, whilst 216 
reduced numbers of persisters were present at 14 weeks of treatment. At 8 weeks of 217 
treatment, there were low numbers of persisters present after treatment with rifampicin 30 218 
mg/kg regimen, complete persister eradication was seen at 11 weeks. There were no 219 
persistent bacteria at 8, 11 and 14 week for rifampicin 40 mg/kg treatment. The regimen 220 
containing 50 mg/kg rifampicin, although failed to clear persisters  at 6 week,  showed no 221 
CF-resuscitated bacilli in both lungs and spleens at 8, 11 and 14 weeks of treatment  (Table 222 
4).  223 
Relapse rate of treatment with the regimens containing different doses of rifampicin 224 
in the Cornell model 225 
The organ cfu counts are shown in Table 5. The treatment with the regimen containing 10 226 
mg/kg of rifampicin gave rise to M. tuberculosis positive organs in 19 out of 23 mice (86.3% 227 
relapse rate). 20 mg/kg rifampicin containing regimen led to 33% relapse rate after 14 weeks 228 
of treatment. In contrast, treatment with the regimens containing 30, 40 and 50 mg/kg of 229 
rifampicin resulted in zero counts in the organs showing relapse free (P < 0.001).  230 
DISCUSSION 231 
TB drug regimens capable of eradicating persistent bacilli likely have the greatest clinical 232 
value to shorten the treatment duration and reduce relapse rate.  In this study, the efficacy of a 233 
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dose range for rifampicin in the standard drug regimen was studied and CF-dependent 234 
persisters were quantified at the time points when cfu count free organs were reached in the 235 
Cornell mouse model. We intended to define if we could utilize CF-dependent persistent M. 236 
tuberculosis as a biomarker for assessment of TB treatment outcome. The Cornell model is a 237 
reliable surrogate for efficacy in tuberculosis focused on disease relapse, developed more 238 
than 60 years ago by McCune et al.
22, 23
  It has been used to assess the pharmacodynamics of 239 
TB drug regimens and pave the way for drugs from critical preclinical evaluation to clinical 240 
application.
29
  Our previous results demonstrated that RPF-dependent bacilli constituted a 241 
major pool for disease relapse in the Cornell model.
13
 It has been repeatedly shown that the 242 
standard rifampicin dose (10 mg/kg) regimen was unable to eliminate the undetectable 243 
persistent bacteria leading to a high disease relapse.
8, 13, 24
 With high dose rifampicin (50 244 
mg/kg) regimen, treatment duration was shortened from 14 to 6 weeks and free of relapse. 
13
 245 
This was attributed to the eradication of CF-responsive persistent bacilli from the infected 246 
organs. In this study, we showed that double the standard dose size of rifampicin failed to 247 
remove CF-dependent persisters at both 11 weeks and 14 weeks of treatment with a relapse 248 
rate of 33% (Table 5). When the drug reached 30 mg/kg, cfu count zero was achieved at 8 249 
weeks with low number of CF-dependent persisters and a further treatment period (up to 11 250 
weeks) was needed to sterilize the organs (Table 4). The regimens with rifampicin at 40 and 251 
50 mg/kg rendered true tubercle bacilli-sterility (negativity for both cfu count and CF-252 
resuscitatable bacteria) in lungs and spleens at 8 weeks of treatment.  253 
We present clear evidence that we were able to predict disease relapse by assessing CF-254 
dependent persisters.  For the first time, we demonstrated that in mice, rifampicin dose size of 255 
30 mg/kg (a minimum threshold) or higher was able to eradicate persistent bacilli leading to 256 
about 21 to 43% shortened treatment period with no disease relapse. Based on this 257 
observation, it may be argued that patients treated with higher than 30 mg/kg of rifampicin 258 
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are likely to achieve cfu count negative sputum faster with low number or no persistent 259 
bacteria leading to shortened treatment duration. This is evidenced in humans, that rifampicin 260 
at 35 mg/kg was able to improve time to stable culture conversion in liquid media 
20
 although 261 
treatment outcome is unknown in term of treatment duration and relapse. Our data offered a 262 
potential prediction of high dose rifampicin at 30 to 50 mg/kg to improve current clinical 263 
treatment, namely shortening the treatment duration and reducing relapse. This highly 264 
promising proof-of-principle work has pioneered a novel clinical method to identify and 265 
quantify persistent bacteria by RPF resuscitation to assess the clinical effectiveness of higher 266 
dose rifampicin in humans (A. Jindani, St George’s University of London, personal 267 
communications).  268 
In addition, we demonstrated that rifampicin in combination with isoniazid and pryzinimide 269 
showed a linear relationship between its dose level and plasma exposure (Cmax and AUC) in 270 
both uninfected and infected mice. We also showed that the plasma exposures of rifampicin 271 
were similar in both infected and uninfected animals (Fig. 2). The drug exposures were about 272 
two fold higher than those in our previous and other group’s reports.
13, 14, 17, 19
  Importantly, 273 
the rifampicin dose linearity of plasma exposure coincided with the linear trend in cfu count 274 
elimination (Fig. 1). There was a clear linearity of the bacterial elimination rate constant as a 275 
measure of efficacy with increasing dose of rifampicin within the range of doses examined 276 
(Fig 1).  Similarly, the dose-dependent drug exposure of rifampicin is closely associated with 277 
the persistent bacterial elimination at the time points when cfu counts were negative. The 278 
linear trend in elimination rate constant was in agreement with the deduction of persister 279 
counts and relapse rate, namely faster elimination rates at higher doses concurred with lower 280 
persister counts and lower relapse rates.  The same may be true in humans because 281 
interestingly, the linearity of rifampicin plasma exposure with dose shown in this study is 282 
consistent with the linearity of rifampicin PK over the range of 10 to 35 mg/kg in humans.
14
   283 
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It has been shown that in the standard dose of rifampicin (10 mg/kg), 90% of the drug was  284 
bound to human plasma proteins 
30
 and 97% was  bound to mouse proteins,
19
 therefore, only 285 
a very low amount of free drug was able to diffuse into tuberculous lesions. Here we showed 286 
that increasing dose of rifampicin exhibited an accelerated dose-dependent eradication of 287 
persistent bacteria (Table 4). When rifampicin concentration was increased to 30 mg/kg and 288 
above, high blood Cmax and AUC were achieved, leading to higher levels of biologically 289 
available rifampicin which were able to kill persistent bacteria.
13
  290 
The drug exposure and the unbound drug for the same dose size between mice and humans 291 
are different for rifampicin. In mice, AUCs and Cmax of rifampicin are at least threefold 292 
higher than those in humans. In contrast, the free fraction of the drug is almost threefold 293 
greater in humans than that in mice. This suggests that the levels of the active and free drug 294 
in mice leading to the greater efficacy shown in this study can be effectively reached in 295 
humans at the dose levels which were currently studied in human clinical trials. 296 
The implication of our mouse data to patient’s benefits must be taken with caution. 297 
Tuberculosis in humans and in mice differs in the histopathology of the disease. In humans, 298 
TB rarely kills the host in the initial infection. Active disease is associated with a wide range 299 
of granuloma lesions, including bacterial bearing, necrotic granulomas undergoing central 300 
liquefaction and large open cavities, as well as closed granulomas with central caseum, 301 
fibrotic and calcified lesions. In contrast, in the standard Cornell model, infection is initiated 302 
by a high dose of M. tuberculosis (10
5
 cfu/mouse) and treatment is commenced 2 to 3 weeks 303 
after infection  when adaptive immunity is just established. There are no granuloma-like 304 
structures in the lungs.  305 
In conclusion, the current recommended dosage of rifampicin at 10 mg/kg is insufficient to 306 
kill persistent bacilli in the Cornell mouse model. Rifampicin at 30 mg/kg or higher in 307 
combination with isoniazid and pyrazinamide significantly shortened the treatment and 308 
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prevented disease relapse by removing persistent bacteria. PK exposure of rifampicin and the 309 
observed cfu elimination rate constants were both linear in the range of rifampicin doses from 310 
10 to 50 mg/kg in the combination therapy. Optimizing rifampicin to its maximal therapeutic 311 
efficacy with acceptable side-effect profiles will provide valuable information in human 312 
studies and can potentially revolutionize current tuberculosis chemotherapy.  313 
314 
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 403 
 404 
Figure legends 405 
Figure 1. Treatment profiles of M. tuberculosis H37Rv with different dose size of rifampicin 406 
(R) in combination with isoniazid (H) and pyrazinamide (Z) in the Cornell mouse model. a. 407 
Elimination of cfu counts in lungs. b. Elimination of cfu counts in spleens. The solid arrow 408 
indicates the treatment starting at 3 weeks of post infection. The empty arrow indicates 409 
starting steroid treatment after the termination of 14 week therapy.  c. Elimination rate 410 
constant against rifampicin doses in lungs. d. Elimination rate constant against rifampicin 411 
doses in spleens.  412 
Figure 2. Rifampicin pharmacokinetic relationship between dose sizes and drug exposure in 413 
infected and uninfected mice. a. Linear relationship between rifampicin dose and Cmax. b. 414 
Linear relationship between rifampicin dose and AUC. c. Clearance of rifampicin with 415 
different dose sizes of the drug.  416 
 417 
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Table 1. Cornell model experimental design 
Treatment groups
a
 No. of mice
b
 D0 D21 2W 4W 6W 8W 11W 14W 22W
c
 
Control 8 4 4 
       R10HZ 71 
 
8 8 8 8 8 8 23 
R20HZ 71 8 8 8 8 8 8 23 
R30HZ 71 8 8 8 8 8 8 23 
R40HZ 71 8 8 8 8 8 8 23 
R50HZ 71 
  
8 8 8 8 8 8 23 
a Mice were intravenously infected at day 0. Treatment commenced at 21 days after infection. 
Dosages for each drug were as follows: rifampicin (R) 10, 20, 30, 40 or 50 mg/kg, isoniazid 
(H) 25 mg/kg and pryzinimide (Z) 150 mg/kg. 
b Total mice were infected and treated excluding natural death of the mice during the course 
of treatment 
c 8 weeks of hydrocortisone treatment post 14 weeks of treatment   
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Table 2. Bactericidal and sterilizing activities of the experimental regimens against M. 
tuberculosis in mouse lungs and spleens 
Organs Time Control R10HZ R20HZ R30HZ R40HZ R50HZ 
Lung D0
a
 4.36 ± 0.26 
    D21
b
 6.93 ± 0.07 
2 weekc 5.58 ± 0.43 5.12 ± 0.14 4.68 ± 0.27 4.35 ± 0.29 4.00 ± 0.23 
4 week 4.58 ± 0.33 4.12 ± 0.06 3.35 ± 0.46 2.80 ± 0.41 1.99 ± 0.02 
6 week 3.71 ± 0.05 3.08 ± 0.52 1.88 ± 0.70 1.14 ± 0.62 0 
8 week 2.58 ± 0.27 1.95 ± 0.43 0 0 0 
11 week 1.01 ± 0.43 0 0 0 0 
14 week 0 0 0 0 0 
Spleen D0a 5.30 ± 0.16 
 
D21b 7.43 ± 0.21 
    
 
2 week
c
 6.36 ± 0.29 5.73 ± 0.96 5.07 ± 0.52 4.61 ± 0.56 3.94 ± 0.46 
4 week 5.20 ± 0.23 4.17 ± 0.48 3.24 ± 0.13 2.00 ± 0.48 1.40 ± 0.42 
6 week 3.65 ± 0.45 2.54 ± 0.49 1.69 ± 0.46 0 0 
8 week 2.34 ± 0.36 1.49 ± 0.53 0 0 0 
11 week 0.92 ± 0.46 0 0 0 0 
14 week 0 0 0 0 0 
a. 2 hours post-infection. b. 21 days post-infection. c. week 2 post-treatment.   
Zero cfu count from each drug regimen was derived from one third of tissue homogenate 
and limit detection was 3 cfu/organ. 
The data presented as mean of 4 mice for the control and 8 mice for the treatment groups        
with standard deviation.  
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Table 3. Estimates of exponential rate constants during pre-treatment (knet_no_drug) and 
treatment (knet_with_drug) in mouse lungs and spleens 
 
 
Elimination rate constant (wk-1) 
Treatment group Lungs Spleens  
 
est.a %RSEb est.a %RSEb 
R10HZ -0.52 2.0 -0.56 3.4 
R20HZ -0.58 4.9 -0.69 6.3 
R30HZ -0.75 8.2 -0.88 5.4 
R40HZ -0.84 6.2 -1.32 6.7 
R50HZ -1.07 5.2 -1.40 6.9 
a
 estimate. 
b
 percentage relative standard error. 
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Table 4. Resuscitation of M. tuberculosis H37Rv in mouse lungs and spleens in the Cornell 
mouse model after treatment with regimens containing different doses of rifampicin 
  
MPN counts (CF)
a
 
Organs Weeks of treatment R10HZ R20HZ R30HZ R40HZ R50HZ 
Lung 6 - - - - 1 ± 4 
 
8 - - 9 ± 9 0 0 
11 - 90 ± 30 0 0 0 
14 245 ± 28 20 ± 23 0 0 0 
Spleen 6 - - - - 3 ± 5 
 
8 - - 18 ± 10 0 0 
 
11 - 122 ± 83 0 0 0 
14 308 ± 440 58 ± 21 0 0 0 
a
determined by MPN of the diluted organ homogenies (n=8)  with the culture filtrates, mean 
MPN ± standard deviations.  Broth counts were derived from one third of tissue homogenate 
and calculated to represent the MPN of entire organ. The limit of detection was 1 
MPN/organ. -, Colony count positive and MPN counts not performed organs.  
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Table 5. Relapse rates of mice after treatment with regimens containing different doses of 
rifampicin for 14 weeks 
CFU counts detected from R10HZ R20HZ R30HZ R40HZ R50HZ 
Both organs 6 1 0 0 0 
Lungs 7 5 0 0 0 
Spleens 6 2 0 0 0 
Negative organs 3 16 22 23 22 
Total mice 22 24 22 23 22 
% relapse 86.36 33 0 0 0 
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